ASTA Comments to FDA on Voluntary Sesame Labeling Guidance
ASTA issued comments to the Food and Drug Administration (FDA) in February 2021 on the Voluntary Disclosure of Sesame as an Allergen: Guidance for Industry. Comments outline inconsistencies and confusion arising from the guidance, including that FDA policy already provides that sesame should not be labeled under the generic declaration of spices. ASTA requests that FDA revoke the voluntary guidance due to the legislative process and the FASTER Act.
Membership Required
A valid ASTA membership is required to access this page. Please use the form below to log in with your ASTA member account.
Log in
Not a member yet? Click here to learn about joining ASTA today.
Related Resources
NCFIA Comments Regarding FDA/CBP Coordination on Prior Notice Requirements
NCFIA issued comments to the Food and Drug Administration in May 2004 regarding joint FDA and Customs and Border Protection plans for increasing integration and assessing the coordination of prior notice timeframes.
ASTA Draft Risk Profile Comments
ASTA issued a comment to the Food and Drug Administration (FDA) in March 2014 regarding the FDA's Draft Risk Profile on Pathogens and Filth in Spice.
